For more information about genetic testing, please visit [ Ссылка ]

The content of this webinar is primarily based on a recent publication involving a large laboratory-based multigene panel cohort. First, gene-specific cancer risk associations will be presented, which were derived from comparing multigene panel testing cases to reference controls from gnomAD. Next, the attendee will be navigated through the prevalence of pathogenic variants among different clinical testing indications. Finally, the sensitivity of BRCA1/2 and Lynch syndrome testing criteria will be explored, with a focus on opportunities to improve upon identification of individuals with cancer-predisposing germline variants.

Presented by:
Holly LaDuca, MS, CGC
Sarah Campian, MS, CGC

Ms. LaDuca is a board-certified genetic counselor. In her current role as Sr. Manager of Clinical Affairs Research at Ambry Genetics, Ms. LaDuca oversees clinical research efforts, focusing on the translational application of Ambry’s research. She also oversees clinical data management and data sharing efforts. Her research interests include clinical implementation of polygenic risk scores and improving access to risk assessment and genetic testing. Ms. LaDuca received her M.S. in Genetic Counseling from Northwestern University and practiced clinically as a cancer genetic counselor prior to joining Ambry eight years ago.

свернуть